Clinical remission · Patients with active Crohn's disease
Budesonide 9 mg probably leads to lower induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with conventional steroids (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with conventional steroids (low certainty).
1 finding from 1 review
Withdrawal due to disease worsening · Patients with active Crohn's disease
It is very uncertain whether budesonide 9 mg changes withdrawal due to disease worsening compared with conventional steroids (very low certainty).
1 finding from 1 review
Clinical improvement · patients with induction of remission in ulcerative colitis
It is very uncertain whether UFH changes clinical improvement compared with corticosteroids (very low certainty).
1 finding from 1 review
Failure to achieve complete resolution (combined for face and scalp) Clinical assessment · patients with seborrhoeic dermatitis
Ketoconazole showed no clear difference in failure to achieve complete resolution (combined for face and scalp)… compared with steroids (low certainty).
1 finding from 1 review
Failure to achieve complete resolution (long term, combined for face and scalp) Clinical assessment · patients with seborrhoeic dermatitis
1 finding from 1 review
Side effects (combined for face and scalp) Self report · patients with seborrhoeic dermatitis
Ketoconazole probably leads to lower side effects (combined for face and scalp) Self report compared with steroids (moderate certainty).
1 finding from 1 review
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).
3 findings from 1 review
RR 3.09 [2.14, 4.45]
1 study · 371 participants
Moderate
RR 0.95 [0.78, 1.16]
1 study · 377 participants
Low
RR 1.32 [1.17, 1.49]
1 study · 972 participants
Moderate
Participant's self‐assessment of global response of improvement: tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher participant's self‐assessment of global response of improvement:… compared with corticosteroids (moderate certainty).
1 finding from 1 review
Adverse effects ‐ burning · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone… compared with corticosteroids (moderate certainty).
3 findings from 1 review
RR 2.91 [1.6, 5.28]
1 study · 371 participants
Moderate
RR 4.59 [3.1, 6.78]
1 study · 377 participants
Moderate
RR 3.79 [2.99, 4.81]
1 study · 972 participants
Moderate
Participant's self‐assessment of global response of improvement · people with atopic dermatitis
Tacrolimus 0.1% may leads to higher participant's self‐assessment of global response of improvement compared with corticosteroids (low certainty).
1 finding from 1 review
Annual Exacerbation Rates · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Change in quality of life: SGRQ Scale: 0 to 100 · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
FEV1 · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality · patients with stable chronic obstructive pulmonary disease
Summary of findings table ‐ ICS showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Pneumonia · patients with stable chronic obstructive pulmonary disease
Summary of findings table ‐ ICS may leads to higher pneumonia compared with placebo (low certainty).
1 finding from 1 review
Oropharyngeal candidiasis · patients with stable chronic obstructive pulmonary disease
Summary of findings table ‐ ICS probably leads to higher oropharyngeal candidiasis compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Presence of PHN 6 months after the onset of acute herpetic rashClinical manifestation · people with acute herpes zoster (within 7 days of onset of rash)
It is very uncertain whether the intervention changes presence of PHN 6 months after the onset of acute herpetic… (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse eventsClinical manifestation and laboratory examination · people with acute herpes zoster (within 7 days of onset of rash)
It is very uncertain whether the intervention changes serious adverse eventsClinical manifestation and laboratory… (very low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious adverse eventsClinical manifestation and laboratory examination · people with acute herpes zoster (within 7 days of onset of rash)
The intervention showed no clear difference in non‐serious adverse eventsClinical manifestation and laboratory… (low certainty).
1 finding from 1 review